Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: Doxorubicin hydrochloride liposome injection
Sponsor: Luye Pharma Group Ltd.